Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Eating Disorders Post published:September 22, 2021 Post category:Press Release
Bright Minds Biosciences Provides Scientific Update Post published:September 22, 2021 Post category:Press Release
Mycrodose Therapeutics Successfully Completes Oversubscribed Private Placement to Expand Existing Patent Portfolio of Breakthrough Advanced Drug Delivery Technologies Post published:September 21, 2021 Post category:Press Release
Psyched Wellness Initiates a Clinical Sleep Study on Humans for a Structure/Function Claim For AME-1 Post published:September 21, 2021 Post category:Press Release
Small Pharma Successfully Completes Phase I Clinical Trial of DMT in Combination with Supportive Psychotherapy Post published:September 21, 2021 Post category:Press Release
DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder Post published:September 21, 2021 Post category:Press Release
Mindset Pharma Announces Further Preclinical Results Demonstrating Strong Efficacy and Improved Safety Profile for its 5-MeO-DMT-Inspired Drug Candidate, MSP-4018 Post published:September 20, 2021 Post category:Press Release
Psychedelic Bulletin: COMPASS Pathways Acquires IP Portfolio; Wesana to Explore MDMA for TBI With MAPS; Nine Perfect Strangers Draws Attention to Psychedelics Post published:September 17, 2021 Post category:Psychedelic Bulletin
Awakn Life Sciences to Acquire Leading Ketamine-Assisted Psychotherapy Clinic in Norway Post published:September 16, 2021 Post category:Press Release
Former Compass Interim Clinical Sciences Director Joins Clerkenwell Health as CMO Post published:September 16, 2021 Post category:Press Release